[The prospective study of the clinical features and outcome of HBeAg-negative and HBeAg-positive cirrhosis in patients with chronic type B hepatitis].
OBJECTIVE
Comparing clinical features and prognosis between HBeAg-negative and HBeAg-positive cirrhosis in patients with chronic type B hepatitis.


METHODS
217 chronic type B hepatitis with cirrhosis patients were prospectively studied for 35 months (3 - 47 months). Comparing clinical features and prognosis between HBeAg-negative and HBeAg-positive cirrhosis in patients with chronic type B hepatitis.


RESULTS
The numbers of HBeAg-negative cirrhosis in patients with chronic type B hepatitis were more than HBeAg-positive cirrhosis; The median ALT and AST levels of HBeAg-negative patients were lower than HBeAg-positive patients; The median WBC, HGB and PLT levels of HBeAg-negative patients were lower than HBeAg-positive patients; HBV DNA positive rate and proportion of HBV DNA > 10(5) copies/ml of HBeAg-negative patients was lower than HBeAg-positive patients; The mortality rate of HBeAg-negative patients was higher than HBeAg-positive patients; among HBeAg-negative patients group, the presence rate of ascite, portal hypertensive gastrointestinal bleeding and HCC of patients treated with lamivudine were lower than the other patients, the proportion of non-presence of complications patients treated with lamivudine were higher than the other patients, the proportion of presence of one-two complications patients treated with lamivudine were lower than the other patients; among HBeAg-positive patients group, the presence rate of ascite of patients treated with lamivudine were lower than the other patients, the proportion of non-presence of complications patients treated with lamivudine were higher than the other patients.


CONCLUSIONS
Among the liver cirrhosis patients, the numbers of HBeAg-negative cirrhosis were more than HBeAg-positive cirrhosis; HBeAg-negative patients with cirrhosis have lower liver inflammation activity; HBeAg-negative patients with cirrhosis have lower WBC, HGB and PLT levels; HBV DNA positive rate and proportion of HBV DNA > 10(5) copies/ml of HBeAg-negative patients was lower than HBeAg-positive patients; The mortality rate of HBeAg-negative patients was higher than HBeAg-positive patients; Lamivudine treatment is beneficial in HBeAg-negative and HBeAg-positive cirrhosis patients.
Ma
Hui
H
Hepatology Institute, Peking University People's Hospital, Beijing 100044, China.
Guo
Fang
F
Wei
Lai
L
Sun
Yan
Y
Wang
Hao
H
D000328:Adult; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D005500:Follow-Up Studies; D006513:Hepatitis B e Antigens / Q000032:analysis*; D006515:Hepatitis B virus / Q000235:genetics / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000150:complications / Q000401:mortality / Q000821:virology*; D006801:Humans; D008103:Liver Cirrhosis / Q000209:etiology / Q000401:mortality / Q000821:virology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D015996:Survival Rate; D019562:Viral Load
D004279:DNA, Viral; D006513:Hepatitis B e Antigens